perifosine has been researched along with paclitaxel in 2 studies
Studies (perifosine) | Trials (perifosine) | Recent Studies (post-2010) (perifosine) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
---|---|---|---|---|---|
245 | 31 | 140 | 31,874 | 5,729 | 15,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Li, J; Sun, H; Yu, T | 1 |
André, N; Berges, R; Borge, L; Bourgarel, V; Braguer, D; Buric, D; Carré, M; Carrier, A; Le Grand, M; Montero, MP; Pasquier, E; Vasseur, S | 1 |
2 other study(ies) available for perifosine and paclitaxel
Article | Year |
---|---|
Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Survival; Ceramides; Drug Synergism; Female; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |
Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Models, Animal; Energy Metabolism; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mitochondria; Paclitaxel; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |